Petros Pharmaceuticals, Inc.
(NASDAQ : PTPI)

( )
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Daily Pre-Market Movers
Receive our daily pre-market mover email, free.
100% secure: your email is never shared, and you may opt out at any time.
...
Health Technology » Pharmaceuticals Major
symbolcompany%chnglast%shortavg$volume
MRKMerck & Co., Inc. 1.91%78.620.7%$1561.37m
JNJJohnson & Johnson 2.44%164.020.7%$1001.62m
PFEPfizer Inc. 1.42%41.910.9%$929.87m
ABBVAbbVie, Inc. 0.31%107.771.9%$684.08m
BMYBristol-Myers Squibb Co. 0.83%57.411.0%$656.74m
LLYEli Lilly & Co. 0.69%240.631.1%$613.56m
AZNAstraZeneca Plc 1.41%60.121.0%$371.43m
NVSNovartis AG 1.00%83.160.2%$176.09m
GSKGlaxoSmithKline Plc 1.19%39.110.2%$161.87m
RGENRepligen Corp. 1.88%268.746.8%$120.17m
NVONovo Nordisk A/S 1.09%104.560.1%$91.62m
VTRSViatris, Inc. 0.07%13.500.0%$90.63m
EDSAEdesa Biotech, Inc. 6.72%8.260.0%$75.63m
SNYSanofi -0.50%47.790.2%$62.56m
CRVSCorvus Pharmaceuticals, Inc. 0.87%4.660.7%$56.99m

Company Profile

Petros Pharmaceuticals, Inc. engages in men's health therapeutics. It is involved in sales, marketing, regulatory and medical affairs, finance, trade relations, pharmacovigilance, market access relations, manufacturing, and distribution. It operates through the Prescription Medications and Medical Devices segments. The Prescription Medications segment handles Stendra, a FDA approved PDE-5 inhibitor prescription medication for the treatment of erectile dysfunction, and H100, a topical formulation candidate for the treatment of acute Peyronie's disease. The Medical Devices segment consists of vacuum erection devices. The company was founded on May 14, 2020 and is headquartered in New York, NY.